Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 5.465
Filtrer
1.
BMC Pregnancy Childbirth ; 24(1): 459, 2024 Jul 03.
Article de Anglais | MEDLINE | ID: mdl-38961348

RÉSUMÉ

BACKGROUND: To assess pregnancy outcomes in women with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection. METHODS: This was a retrospective cohort study that included pregnant women who contracted coronavirus disease 2019 (COVID-19) once or twice during pregnancy and who gave birth between 1 October 2022 and 15 August 2023 in Shanghai First Maternity and Infant Hospital (Shanghai, China). We collected their clinical data and compared the frequency of adverse pregnancy outcomes between the reinfection group and the primary infection group, such as preterm birth, fetal growth restriction (FGR), hypertensive disorders of pregnancy (HDP), common pregnancy-related conditions, birth weight, and neonatal unit admission. RESULTS: We observed a 7.7% reinfection rate among the 1,405 women who contracted COVID-19 during pregnancy. There were no significant differences in the frequency of preterm birth, FGR, HDP, other common pregnancy-related conditions, birth weight, or rate of neonatal unit admission between the reinfection and single infection groups. All our participants were unvaccinated, and all had mild symptoms. CONCLUSION: Our study showed no significant association between SARS-CoV-2 reinfection and adverse pregnancy outcomes.


Sujet(s)
COVID-19 , Complications infectieuses de la grossesse , Issue de la grossesse , Réinfection , SARS-CoV-2 , Humains , Femelle , Grossesse , COVID-19/épidémiologie , COVID-19/complications , Études rétrospectives , Complications infectieuses de la grossesse/épidémiologie , Complications infectieuses de la grossesse/virologie , Adulte , Issue de la grossesse/épidémiologie , Chine/épidémiologie , Réinfection/épidémiologie , Naissance prématurée/épidémiologie , Nouveau-né , Retard de croissance intra-utérin/épidémiologie
2.
Zhonghua Gan Zang Bing Za Zhi ; 32(6): 532-544, 2024 Jun 20.
Article de Chinois | MEDLINE | ID: mdl-38964896

RÉSUMÉ

Objective: To systematically evaluate the effect of hepatitis B virus (HBV) infection on the risk of adverse pregnancy outcomes. Methods: We searched PubMed, Embase, Web of Science, and Cochrane databases. Two researchers independently screened the literature, extracted data, and evaluated the quality. Meta-analysis and cumulative meta-analysis were performed using R4.4.1 software. Fixed/random effects models were used to analyze heterogeneous and non-heterogeneous results. Heterogeneous modifiers were identified by subgroup analysis. Funnel plots and Peters' test were used to analyze potential publication bias. Results: A total of 48 studies involving 92 836 HBsAg-positive pregnant women and 7 123 292 HBsAg-negative pregnant women were included. In terms of adverse pregnancy outcomes, HBV infection was significantly correlated with the occurrence of gestational diabetes mellitus [odds ratio (OR)=1.34, 95% confidence interval (CI): 1.17-1.53] and intrahepatic cholestasis (OR=2.48, 95%CI: 1.88-3.29), with statistically significant differences. In terms of adverse neonatal outcomes, HBV infection was significantly correlated with the occurrence of neonatal asphyxia (OR=1.49, 95%CI: 1.20-1.86) and preterm birth (OR=1.22, 95%CI: 1.12-1.33), with statistically significant differences. In addition, the cumulative meta-analysis demonstrated that the risk of gestational diabetes mellitus and preterm birth both tended to be stable in pregnant women with HBV infection following 2009 and 2010, respectively. The supplementary questions answered for repeated studies had limited significance. Conclusion: Intrahepatic cholestasis, gestational diabetes mellitus, neonatal asphyxia, and preterm birth occurrence risk can be raised with HBV infection in pregnant women.


Sujet(s)
Hépatite B , Complications infectieuses de la grossesse , Issue de la grossesse , Humains , Grossesse , Femelle , Hépatite B/épidémiologie , Hépatite B/complications , Complications infectieuses de la grossesse/virologie , Complications infectieuses de la grossesse/épidémiologie , Virus de l'hépatite B , Diabète gestationnel/épidémiologie , Naissance prématurée/épidémiologie , Nouveau-né , Cholestase intrahépatique/épidémiologie , Facteurs de risque
3.
FASEB J ; 38(13): e23799, 2024 Jul 15.
Article de Anglais | MEDLINE | ID: mdl-38979938

RÉSUMÉ

Maternal Zika virus (ZIKV) infection during pregnancy has been associated with severe intrauterine growth restriction (IUGR), placental damage, metabolism disturbances, and newborn neurological abnormalities. Here, we investigated the impact of maternal ZIKV infection on placental nutrient transporters and nutrient-sensitive pathways. Immunocompetent (C57BL/6) mice were injected with Low (103 PFU-ZIKVPE243) or High (5 × 107 PFU-ZIKVPE243) ZIKV titers at gestational day (GD) 12.5, and tissue was collected at GD18.5 (term). Fetal-placental growth was impaired in male fetuses, which exhibited higher placental expression of the ZIKV infective marker, eukaryotic translation initiation factor 2 (eIF2α), but lower levels of phospho-eIF2α. There were no differences in fetal-placental growth in female fetuses, which exhibited no significant alterations in placental ZIKV infective markers. Furthermore, ZIKV promoted increased expression of glucose transporter type 1 (Slc2a1/Glut1) and decreased levels of glucose-6-phosphate in female placentae, with no differences in amino acid transport potential. In contrast, ZIKV did not impact glucose transporters in male placentae but downregulated sodium-coupled neutral amino acid 2 (Snat2) transporter expression. We also observed sex-dependent differences in the hexosamine biosynthesis pathway (HBP) and O-GlcNAcylation in ZIKV-infected pregnancies, showing that ZIKV can disturb placental nutrient sensing. Our findings highlight molecular alterations in the placenta caused by maternal ZIKV infection, shedding light on nutrient transport, sensing, and availability. Our results also suggest that female and male placentae employ distinct coping mechanisms in response to ZIKV-induced metabolic changes, providing insights into therapeutic approaches for congenital Zika syndrome.


Sujet(s)
Développement foetal , Souris de lignée C57BL , Placenta , Transduction du signal , Infection par le virus Zika , Virus Zika , Animaux , Femelle , Infection par le virus Zika/métabolisme , Infection par le virus Zika/virologie , Grossesse , Souris , Placenta/métabolisme , Placenta/virologie , Mâle , Développement foetal/physiologie , Complications infectieuses de la grossesse/virologie , Complications infectieuses de la grossesse/métabolisme , Nutriments/métabolisme , Transporteur de glucose de type 1/métabolisme
4.
PLoS One ; 19(7): e0307102, 2024.
Article de Anglais | MEDLINE | ID: mdl-38995928

RÉSUMÉ

INTRODUCTION: Hepatitis B virus (HBV) is one of the major public health problems globally and needs an urgent response. It is one of the most responsible causes of mortality among the five hepatitis viruses, and it affects almost every class of individuals. Different studies were conducted on the prevalence of HBV among pregnant women in East African countries, but none of them showed the pooled prevalence of HBV among the pregnant women. Thus, the main objective of this study was to determine the pooled prevalence and its determinants among pregnant women in East Africa. METHODS: We searched studies using PubMed, Scopus, Embase, ScienceDirect, Google Scholar and grey literature that were published between January 01/2020 to January 30/2024. The studies were assessed using the Newcastle Ottawa Scale (NOS) quality assessment scale. The random-effect (DerSimonian) model was used to determine the pooled prevalence and associated factors of HBV among pregnant women. Heterogeneity were assessed by I2 statistic, sub-group analysis, and sensitivity analysis. Publication bias was assessed by Egger test, and the analysis was done using STATA version 17. RESULT: A total of 45 studies with 35639 pregnant women were included in this systematic review and meta-analysis. The overall pooled prevalence of HBV among pregnant women in East Africa was 6.0% (95% CI: 6.0%-7.0%, I2 = 89.7%). The highest prevalence of 8% ((95% CI: 6%, 10%), I2 = 91.08%) was seen in 2021, and the lowest prevalence 5% ((95% CI: 4%, 6%) I2 = 52.52%) was observed in 2022. A pooled meta-analysis showed that history of surgical procedure (OR = 2.14 (95% CI: 1.27, 3.61)), having multiple sexual partners (OR = 3.87 (95% CI: 2.52, 5.95), history of body tattooing (OR = 2.55 (95% CI: 1.62, 4.01)), history of tooth extraction (OR = 2.09 (95% CI: 1.29, 3.39)), abortion history(OR = 2.20(95% CI: 1.38, 3.50)), history of sharing sharp material (OR = 1.88 (95% CI: 1.07, 3.31)), blood transfusion (OR = 2.41 (95% CI: 1.62, 3.57)), family history of HBV (OR = 4.87 (95% CI: 2.95, 8.05)) and history needle injury (OR = 2.62 (95% CI: 1.20, 5.72)) were significant risk factors associated with HBV infection among pregnant women. CONCLUSIONS: The pooled prevalence of HBV infection among pregnant women in East Africa was an intermediate level and different across countries ranging from 1.5% to 22.2%. The result of this pooled prevalence was an indication of the need for screening, prevention, and control of HBV infection among pregnant women in the region. Therefore, early identification of risk factors, awareness creation on the mode of transmission HBV and implementation of preventive measures are essential in reducing the burden of HBV infection among pregnant women.


Sujet(s)
Hépatite B , Complications infectieuses de la grossesse , Humains , Femelle , Grossesse , Afrique de l'Est/épidémiologie , Hépatite B/épidémiologie , Prévalence , Complications infectieuses de la grossesse/épidémiologie , Complications infectieuses de la grossesse/virologie , Virus de l'hépatite B/isolement et purification , Facteurs de risque
5.
PLoS One ; 19(7): e0305838, 2024.
Article de Anglais | MEDLINE | ID: mdl-39012904

RÉSUMÉ

INTRODUCTION: Africa exhibits a considerably high prevalence of the hepatitis B virus among pregnant women. Furthermore, there is a discernible lack of a well-established surveillance system to adequately monitor and comprehend the epidemiology of the hepatitis B virus, particularly among pregnant women. The eradication efforts of the virus in Africa have been impeded by the significant disease burden in the region, and there is a lack of evidence regarding the pooled prevalence of the hepatitis B virus in Africa. Consequently, this systematic review and meta-analysis aims to determine the prevalence of hepatitis B virus infection among pregnant women in Africa. METHODS: We conducted a systematic literature search using reputable databases such as PubMed, Advanced Google Scholar, Scopus, and the Cochrane Library. The search spanned from July 2013 to July 2023 and included all relevant articles published within this period. To identify potentially eligible articles, we conducted a comprehensive manual review of the reference lists of the identified studies. Our review encompassed articles from the African Journal Online. The analysis focused on observational studies published in peer-reviewed journals that reported the prevalence of hepatitis B surface antigen-positive testing among pregnant women. We utilized the Newcastle-Ottawa critical appraisal checklist to assess the methodological quality of each paper. Finally, a meta-analysis was conducted using a random-effects model. RESULTS: Out of the 774 studies identified, 31 studies involving 33,967 pregnant women were selected for the meta-analysis. According to the random-effects model, the combined prevalence of hepatitis B virus among pregnant women was 6.77% [95% CI: 5.72, 7.83]. The I2 statistic was calculated to be 95.57% (p = 0.00), indicating significant heterogeneity among the studies. The high I2 value of 95.57% suggests a substantial degree of heterogeneity. A subgroup meta-analysis revealed that factors such as time-dependent bias, sample size dependence, or individual variation among study participants contributed to this heterogeneity (p-difference < 0.05). CONCLUSION: According to the findings of this study, the pooled prevalence of hepatitis B infection among pregnant women in Africa was found to be intermediate-high. It is recommended that policymakers implement hepatitis B virus immunization programs targeting pregnant women and their new-born babies at higher risk of exposure.


Sujet(s)
Virus de l'hépatite B , Hépatite B , Complications infectieuses de la grossesse , Humains , Grossesse , Femelle , Hépatite B/épidémiologie , Prévalence , Afrique/épidémiologie , Complications infectieuses de la grossesse/épidémiologie , Complications infectieuses de la grossesse/virologie
6.
Gen Physiol Biophys ; 43(4): 313-319, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38953573

RÉSUMÉ

The work presents the connection between the infection of COVID-19 during pregnancy and non-syndromic orofacial clefts (NSOFC). Aim of the study was to compare the incidence of COVID-19 disease during mother´s pregnancy between a group of the children with NSOFC and a control group of the children without NSOFC. COVID-19 was confirmed by polymerase chain reaction (PCR) test. The study showed significantly higher incidence of COVID-19 disease in the group of mothers who gave birth to a child with NSOFC in comparison to the group of mothers who gave birth to a child without NSOFC. Our results indicate the possible participation of the infection of COVID-19 in the formation of NSOFCs.


Sujet(s)
COVID-19 , Bec-de-lièvre , Fente palatine , Complications infectieuses de la grossesse , Humains , Bec-de-lièvre/épidémiologie , Fente palatine/épidémiologie , COVID-19/épidémiologie , Femelle , Grossesse , Complications infectieuses de la grossesse/épidémiologie , Complications infectieuses de la grossesse/virologie , Incidence , Adulte , Mâle , Nouveau-né
8.
HIV Res Clin Pract ; 25(1): 2378575, 2024 Dec.
Article de Anglais | MEDLINE | ID: mdl-39012073

RÉSUMÉ

BACKGROUND: Globally, the rate of antiretroviral therapy coverage for pregnant women living with human immunodeficiency virus (HIV) increased by 38% between 2010 and 2015 but only by 2% between 2016 and 2020. OBJECTIVES: We aimed to determine the prevalence of vertical transmission of HIV among infants from mothers living with HIV and associated factors in the Eastern Lake Zone and Southern Highland of Tanzania from January to December 2022. METHODS: This retrospective cross-sectional study extracted data from the Open Laboratory Data Repository database collected from January to December 2022 at 93 health facilities. A total of 1,411 infants exposed to HIV from the Mbeya (851), Songwe (304), and Mara regions (256) were enrolled. RESULTS: The prevalence for vertical transmission of HIV was 2.48% (35/1411). We observed a non-significant difference in the prevalence of vertical transmission in children whose first test was done below six weeks of life (1.89%) and other age groups (2.52-2.62%) (p < 0.917). Children not given antiretroviral prophylaxis had eleven times higher odds of acquiring infection (AOR 11.39, 95% CI: 3.61-35.97). Mothers who were not on ART during pregnancy had three times the odds of transmitting HIV to their infants (AOR 3.03, 95%CI: 0.91-10.15). CONCLUSIONS: We found a low prevalence of vertical transmission of HIV compared to previous studies done in Tanzania. The use of ART prophylaxis for infants exposed to HIV is significantly associated with the low rate of HIV transmission.


Sujet(s)
Infections à VIH , Transmission verticale de maladie infectieuse , Complications infectieuses de la grossesse , Humains , Transmission verticale de maladie infectieuse/statistiques et données numériques , Tanzanie/épidémiologie , Infections à VIH/transmission , Infections à VIH/épidémiologie , Infections à VIH/traitement médicamenteux , Études transversales , Femelle , Prévalence , Études rétrospectives , Nourrisson , Adulte , Grossesse , Mâle , Nouveau-né , Complications infectieuses de la grossesse/épidémiologie , Complications infectieuses de la grossesse/virologie , Complications infectieuses de la grossesse/traitement médicamenteux , Jeune adulte , Facteurs de risque
9.
Viruses ; 16(6)2024 May 29.
Article de Anglais | MEDLINE | ID: mdl-38932160

RÉSUMÉ

Infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) in pregnancy are associated with the development of preeclampsia and fetal growth restriction (FGR). Recently, preeclampsia was linked to impaired maternal hemodynamic function. This retrospective study evaluated singleton pregnancies with COVID-19 during pregnancy and healthy pregnant controls matched for gestational age from November 2020 to March 2022. Non-invasive assessment of maternal hemodynamics by continuous wave Doppler ultrasound measurements (USCOM-1A® Monitor) and oscillometric arterial stiffness (Arteriograph) was performed. Overall, 69 pregnant women were included-23 women after COVID-19 during pregnancy and 46 healthy controls. While two women (8.7%) were admitted to the hospital due to COVID-19-related symptoms, none required intensive care unit admission or non-invasive/invasive ventilation. There were no statistically significant differences in the majority of hemodynamic parameters between the two cohorts. The prevalence of FGR was significantly higher in the COVID-19 during pregnancy group (9.5% vs. healthy controls: 0.0%; p = 0.036), especially in nulliparous women. No difference in angiogenic markers and neonatal outcomes were observed between pregnant women after COVID-19 and healthy controls. In conclusion, no significant differences in hemodynamic parameters or neonatal outcome were observed in women with COVID-19 during pregnancy. However, an increased prevalence of FGR could be described.


Sujet(s)
COVID-19 , Retard de croissance intra-utérin , Hémodynamique , Pré-éclampsie , Complications infectieuses de la grossesse , Issue de la grossesse , SARS-CoV-2 , Humains , Grossesse , Femelle , COVID-19/physiopathologie , COVID-19/diagnostic , Adulte , Complications infectieuses de la grossesse/virologie , Complications infectieuses de la grossesse/physiopathologie , Études rétrospectives , Retard de croissance intra-utérin/physiopathologie , Nouveau-né , Pré-éclampsie/physiopathologie , Marqueurs biologiques/sang
10.
Viruses ; 16(6)2024 May 31.
Article de Anglais | MEDLINE | ID: mdl-38932183

RÉSUMÉ

Congenital cytomegalovirus (cCMV) infection poses significant risks to fetal development, particularly affecting the nervous system. This study reports a fetal autopsy case, examining cCMV infection and focusing on CMV DNA measurements in various fetal organs before formalin fixation, a novel approach for comprehensive CMV DNA evaluations in fetal organs affected by cCMV. A 20-week-old male fetus was diagnosed with cCMV following the detection of CMV DNA in ascites obtained via abdominocentesis in utero. After the termination of pregnancy, multiple organs of the fetus, including the cerebrum, thyroid gland, heart, lungs, liver, spleen, kidneys, and adrenal glands, were extracted and examined for CMV DNA loads using a real-time polymerase chain reaction. Histopathological examination involved hematoxylin-eosin and CMV-specific immunostaining. A correlation was found between CMV DNA loads and pathology, with higher CMV-infected cell numbers observed in organs positively identified with both staining methods, exhibiting CMV DNA levels of ≥1.0 × 104 copies/mL, compared to those detected solely by CMV-specific immunostaining, where CMV DNA levels ranged from 1.0 × 103 to 1.0 × 104 copies/mL. These results highlight a quantifiable relationship between the organ infection extent and CMV DNA concentration, providing insights into cCMV pathogenesis and potentially informing future diagnostic and therapeutic strategies for cCMV infection.


Sujet(s)
Infections à cytomégalovirus , Cytomegalovirus , ADN viral , Foetus , Charge virale , Infections à cytomégalovirus/congénital , Infections à cytomégalovirus/virologie , Infections à cytomégalovirus/diagnostic , Humains , Cytomegalovirus/génétique , Cytomegalovirus/isolement et purification , ADN viral/génétique , Mâle , Femelle , Foetus/virologie , Grossesse , Adulte , Autopsie , Complications infectieuses de la grossesse/virologie
11.
Medicina (Kaunas) ; 60(6)2024 Jun 03.
Article de Anglais | MEDLINE | ID: mdl-38929551

RÉSUMÉ

Background and Objectives: The aim of the present work was to compare the characteristics of delta and omicron variants of COVID-19 infection in pregnant women, the association of infection with comorbidity, clinical manifestation of the disease, type of delivery, and pregnancy outcome. Material and Methods: The study was designed as an observational, retrospective study of a single center. The analysis included the cohort of women who had SARS-CoV-2 infection during pregnancy and/or childbirth in the period from 1 March 2020 to 30 June 2023. Results: Out of a total of 675 pregnant women with SARS-CoV-2 infection, 130 gave birth with the delta and 253 with the omicron variant. In our retrospective analysis, pregnant women with both SARS-CoV-2 variants had a mild clinical history in most cases. In the omicron period, a significantly lower incidence of pregnancy loss (p < 0.01) and premature birth (p = 0.62) admission of mothers and newborns to the intensive care unit (p < 0.05) was recorded. Conclusions: In our retrospective analysis, pregnant women with COVID-19 infection generally exhibited a milder clinical manifestation with both variants (delta and omicron) of the viral infection. During the delta-dominant period, ten percent of affected pregnant women experienced a severe clinical history. However, during the omicron-dominant period infection, a significantly lower incidence of complications, pregnancy loss, preterm delivery, and admission of mothers and neonates to the intensive care unit was recorded. This can be partly explained by the greater presence of pregnant women with natural or induced vaccine immunity.


Sujet(s)
COVID-19 , Complications infectieuses de la grossesse , Issue de la grossesse , SARS-CoV-2 , Humains , Grossesse , Femelle , COVID-19/immunologie , COVID-19/épidémiologie , Études rétrospectives , Complications infectieuses de la grossesse/virologie , Complications infectieuses de la grossesse/épidémiologie , Adulte , SARS-CoV-2/immunologie , Issue de la grossesse/épidémiologie , Nouveau-né , Naissance prématurée/épidémiologie
12.
Mymensingh Med J ; 33(3): 810-816, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38944726

RÉSUMÉ

Objective of the study was the effect of Covid-19 infection on pregnancy and neonatal outcomes. This prospective cohort study was conducted in Combined Military Hospital (CMH) Bogura, Obstetrics and Gynaecology department from June 2020 to October 2020. We have collected and analyzed data of 29 pregnant ladies positive for Covid-19. Control group was Covid-19 negative pregnant patients. Nasopharyngeal swab was taken for real time polymerase chain reaction for detection of Covid-19. We observed symptoms, compared any complication in mother and fetus, mode of termination, and duration of hospital stay. Only six patients were asymptomatic (10.3%). Fifteen (25.9%) had fever, six (6) had weakness (10.3%), 5(8.6%) had sore throat, 3(5.2%) had nausea and 5(8.6%) presented with loss of smell. Among twenty-nine patients, 5(8.6%) delivered normally, 24(41.4%) were delivered through caesarean section which was significantly higher than control group (p value <0.001). No mother became critical or expired, neonatal death was also absent. Mean duration of hospital stay was 14.13±6.192 days in case and 5.18±4.99 in control which was significantly (p value <0.001) higher. Breast feeding was significantly higher in control group (p value <0.001). This study shows feto-maternal outcome of Covid-19 pregnancy is almost same as those of normal pregnancy.


Sujet(s)
COVID-19 , Complications infectieuses de la grossesse , Issue de la grossesse , Humains , Grossesse , Femelle , COVID-19/épidémiologie , Complications infectieuses de la grossesse/virologie , Complications infectieuses de la grossesse/épidémiologie , Complications infectieuses de la grossesse/diagnostic , Adulte , Études prospectives , Bangladesh/épidémiologie , Nouveau-né , SARS-CoV-2 , Durée du séjour/statistiques et données numériques , Césarienne/statistiques et données numériques , Jeune adulte
13.
Nat Commun ; 15(1): 5173, 2024 Jun 18.
Article de Anglais | MEDLINE | ID: mdl-38890352

RÉSUMÉ

Zika virus (ZikV) infection during pregnancy can cause congenital Zika syndrome (CZS) and neurodevelopmental delay in infants, of which the pathogenesis remains poorly understood. We utilize an established female pigtail macaque maternal-to-fetal ZikV infection/exposure model to study fetal brain pathophysiology of CZS manifesting from ZikV exposure in utero. We find prenatal ZikV exposure leads to profound disruption of fetal myelin, with extensive downregulation in gene expression for key components of oligodendrocyte maturation and myelin production. Immunohistochemical analyses reveal marked decreases in myelin basic protein intensity and myelinated fiber density in ZikV-exposed animals. At the ultrastructural level, the myelin sheath in ZikV-exposed animals shows multi-focal decompaction, occurring concomitant with dysregulation of oligodendrocyte gene expression and maturation. These findings define fetal neuropathological profiles of ZikV-linked brain injury underlying CZS resulting from ZikV exposure in utero. Because myelin is critical for cortical development, ZikV-related perturbations in oligodendrocyte function may have long-term consequences on childhood neurodevelopment, even in the absence of overt microcephaly.


Sujet(s)
Modèles animaux de maladie humaine , Gaine de myéline , Oligodendroglie , Infection par le virus Zika , Virus Zika , Animaux , Infection par le virus Zika/virologie , Infection par le virus Zika/anatomopathologie , Oligodendroglie/virologie , Oligodendroglie/métabolisme , Oligodendroglie/anatomopathologie , Femelle , Gaine de myéline/métabolisme , Grossesse , Virus Zika/pathogénicité , Complications infectieuses de la grossesse/virologie , Complications infectieuses de la grossesse/anatomopathologie , Macaca nemestrina , Encéphale/virologie , Encéphale/anatomopathologie , Encéphale/métabolisme , Humains , Protéine basique de la myéline/métabolisme , Protéine basique de la myéline/génétique
14.
J Neuroinflammation ; 21(1): 163, 2024 Jun 25.
Article de Anglais | MEDLINE | ID: mdl-38918792

RÉSUMÉ

BACKGROUND: The SARS-CoV-2 virus activates maternal and placental immune responses. Such activation in the setting of other infections during pregnancy is known to impact fetal brain development. The effects of maternal immune activation on neurodevelopment are mediated at least in part by fetal brain microglia. However, microglia are inaccessible for direct analysis, and there are no validated non-invasive surrogate models to evaluate in utero microglial priming and function. We have previously demonstrated shared transcriptional programs between microglia and Hofbauer cells (HBCs, or fetal placental macrophages) in mouse models. METHODS AND RESULTS: We assessed the impact of maternal SARS-CoV-2 on HBCs isolated from 24 term placentas (N = 10 SARS-CoV-2 positive cases, 14 negative controls). Using single-cell RNA-sequencing, we demonstrated that HBC subpopulations exhibit distinct cellular programs, with specific subpopulations differentially impacted by SARS-CoV-2. Assessment of differentially expressed genes implied impaired phagocytosis, a key function of both HBCs and microglia, in some subclusters. Leveraging previously validated models of microglial synaptic pruning, we showed that HBCs isolated from placentas of SARS-CoV-2 positive pregnancies can be transdifferentiated into microglia-like cells (HBC-iMGs), with impaired synaptic pruning behavior compared to HBC models from negative controls. CONCLUSION: These findings suggest that HBCs isolated at birth can be used to create personalized cellular models of offspring microglial programming.


Sujet(s)
COVID-19 , Macrophages , Microglie , Placenta , Complications infectieuses de la grossesse , SARS-CoV-2 , Femelle , Grossesse , Microglie/virologie , Humains , Placenta/virologie , COVID-19/immunologie , Macrophages/virologie , Complications infectieuses de la grossesse/virologie , Complications infectieuses de la grossesse/anatomopathologie , SARS-CoV-2/pathogénicité , Foetus , Adulte , Encéphale/virologie , Encéphale/anatomopathologie , Souris , Animaux
15.
Zhonghua Gan Zang Bing Za Zhi ; 32(5): 449-452, 2024 May 20.
Article de Chinois | MEDLINE | ID: mdl-38858194

RÉSUMÉ

Objective: To analyze hepatitis B serologic tests and the current prevalence of hepatitis B virus (HBV) infection among pregnant and postpartum women in China from 2021 to 2023. Methods: Data on managing the prevention of mother-to-child transmission of HIV, syphilis, and hepatitis were retrieved from the National Information System. A positive serum HBsAg test was used to define HBV infection. The χ(2) test was used to compare the coverage rate of the hepatitis B serologic test across different years, in early-stage pregnancy, and the current HBV infection in pregnant and postpartum women. A two-sided P value of <0.05 was considered a statistically significant difference. Results: The coverage rate for hepatitis B serological detection in pregnant (including intrapartum) and postpartum women and early-stage pregnancy rose from 99.68% (10 463 059/10 496 883) and 82.96% (8 707 765/10 496 883) to 99.94% (8 678 777/8 684 387, P < 0.001) and 88.87% (7 717 857/8 684 387, P < 0.001) in China between 2021 and 2023. The current prevalence rate of HBV infection decreased from 4.98% (521 479/10 463 059) in 2021 to 4.56% (396 148/8 678 777) in 2023 among pregnant and postpartum women (P < 0.001). The current prevalence rate of HBV infection ranged from 1.53% to 10.39% among pregnant and postpartum women in various provinces of China in 2023. Conclusion: The coverage rate for hepatitis B serologic tests in China increased significantly between 2021 and 2023 in pregnant and postpartum women. Therefore, the current prevalence rate of HBV infection has decreased significantly in pregnant and postpartum women, but a regional difference still exists.


Sujet(s)
Hépatite B , Période du postpartum , Complications infectieuses de la grossesse , Humains , Femelle , Grossesse , Chine/épidémiologie , Hépatite B/épidémiologie , Prévalence , Complications infectieuses de la grossesse/épidémiologie , Complications infectieuses de la grossesse/virologie , Virus de l'hépatite B/isolement et purification , Adulte , Antigènes de surface du virus de l'hépatite B/sang , Transmission verticale de maladie infectieuse/prévention et contrôle
16.
Lancet Glob Health ; 12(7): e1129-e1138, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38876760

RÉSUMÉ

BACKGROUND: Data on long-term neurodevelopmental outcomes of normocephalic children (born with normal head circumference) exposed to Zika virus in utero are scarce. We aimed to compare neurodevelopmental outcomes in normocephalic children up to age 48 months with and without Zika virus exposure in utero. METHODS: In this prospective cohort study, we included infants from two cohorts of normocephalic children born in León and Managua, Nicaragua during the 2016 Zika epidemic. In León, all women pregnant during the two enrolment periods were eligible. In Managua, mother-child pairs were included from three districts in the municipality of Managua: all women who became pregnant before June 15, 2016, and had a due date of Sept 15, 2016 or later were eligible. Infants were serologically classified as Zika virus-exposed or Zika virus-unexposed in utero and were followed up prospectively until age 48 months. At 36 months and 48 months of age, the Mullen Scales of Early Learning (MSEL) assessment was administered. Primary outcomes were MSEL early learning composite (ELC) scores at 30-48 months in León and 36-48 months in Managua. We used an inverse probability weighting generalised estimating equations model to assess the effect of Zika virus exposure on individual MSEL cognitive domain scores and ELC scores, adjusted for maternal education and age, poverty status, and infant sex. FINDINGS: The initial enrolment period for the León cohort was between Jan 31 and April 5, 2017 and the second was between Aug 30, 2017, and Feb 22, 2018. The enrolment period for the Managua cohort was between Oct 24, 2019, and May 5, 2020. 478 mothers (482 infants) from the León cohort and 615 mothers (609 infants) from the Managua cohort were enrolled, of whom 622 children (303 from the León cohort; 319 from the Managua cohort) were included in the final analysis; four children had microcephaly at birth and thus were excluded from analyses, two from each cohort. 33 (11%) of 303 children enrolled in León and 219 (69%) of 319 children enrolled in Managua were exposed to Zika virus in utero. In both cohorts, no significant differences were identified in adjusted mean ELC scores between Zika virus-exposed and unexposed infants at 36 months (between-group difference 1·2 points [95% CI -4·2 to 6·5] in the León cohort; 2·8 [-2·4 to 8·1] in the Managua cohort) or at 48 months (-0·9 [-10·8 to 8·8] in the León cohort; 0·1 [-5·1 to 5·2] in the Managua cohort). No differences in ELC scores between Zika virus-exposed and unexposed infants exceeded 6 points at any time between 30 months and 48 months in León or between 36 months and 48 months in Managua, which was considered clinically significant in other settings. INTERPRETATION: We found no significant differences in neurodevelopmental scores between normocephalic children with in-utero Zika virus exposure and Zika virus-unexposed children at age 36 months or 48 months. These findings are promising, supporting typical neurodevelopment in Zika virus-exposed normocephalic children, although additional follow-up and research is warranted. FUNDING: National Institute of Child Health and Development, National Institute of Allergy and Infectious Diseases, and Fogarty International Center. TRANSLATION: For the Spanish translation of the abstract see Supplementary Materials section.


Sujet(s)
Développement de l'enfant , Complications infectieuses de la grossesse , Effets différés de l'exposition prénatale à des facteurs de risque , Infection par le virus Zika , Humains , Nicaragua/épidémiologie , Infection par le virus Zika/épidémiologie , Femelle , Études prospectives , Enfant d'âge préscolaire , Grossesse , Mâle , Effets différés de l'exposition prénatale à des facteurs de risque/épidémiologie , Effets différés de l'exposition prénatale à des facteurs de risque/virologie , Nourrisson , Complications infectieuses de la grossesse/épidémiologie , Complications infectieuses de la grossesse/virologie , Virus Zika , Adulte , Troubles du développement neurologique/épidémiologie , Troubles du développement neurologique/virologie
17.
PLoS One ; 19(6): e0305331, 2024.
Article de Anglais | MEDLINE | ID: mdl-38857273

RÉSUMÉ

BACKGROUND: High viral load during pregnancy and breastfeeding period is the risk factor for vertical transmission of human immunodeficiency virus (HIV). Currently, Dolutegravir (DTG)-based regimens are recommended to attain adequate viral load suppression (VLS) among women. However, its effect on VLS has not been investigated among women in PMTCT care in Ethiopia. OBJECTIVE: This study aimed to investigate the rate of viral load non-suppression among women exposed to DTG-based versus Efavirenz (EFV)-based regimens in Ethiopia. METHODS: An uncontrolled before-and-after study design was conducted among 924 women (462 on EFV-based and 462 on DTG-based regimens) enrolled in PMTCT care from September 2015 to February 2023. The outcome variable was the viral load (VL) non-suppression among women on PMTCT care. A modified Poisson regression model was employed, and the proportion was computed to compare the rate of VL non-suppression in both groups. The risk ratio (RR) with a 95% confidence interval (CI) was calculated to assess viral load non-suppression among women on DTG-based and EFV-based regimens by adjusting for other variables. RESULTS: The overall rate of non-suppressed VL was 16.2% (95% CI: 14.0-18.8%). Mothers on DTG-based regimens had approximately a 30% (adjusted risk ratio (aRR): 0.70; 95% CI: 0.52-0.94) lesser risk of developing non-suppressed VL than women on EFV-based regimens. Besides, older women were 1.38 times (aRR: 1.38; 95% CI: 1.04-1.83); mothers who did not disclose their HIV status to their partners were 2.54 times (aRR: 2.54; 95% CI: 1.91-3.38); and mothers who had poor or fair adherence to antiretroviral (ARV) drugs were 2.11 times (aRR: 2.11; 95% CI: 1.45-3.07) at higher risk of non-suppressed VL. CONCLUSION: Women on DTG-based regimens had a significantly suppressed VL compared to those on EFV-based regimens. Thus, administering DTG-based first-line ART regimens should be strengthened to achieve global and national targets on VLS.


Sujet(s)
Alcynes , Benzoxazines , Cyclopropanes , Infections à VIH , Composés hétérocycliques 3 noyaux , Oxazines , Pipérazines , Pyridones , Charge virale , Humains , Femelle , Benzoxazines/usage thérapeutique , Charge virale/effets des médicaments et des substances chimiques , Éthiopie/épidémiologie , Composés hétérocycliques 3 noyaux/usage thérapeutique , Adulte , Infections à VIH/traitement médicamenteux , Infections à VIH/virologie , Infections à VIH/épidémiologie , Grossesse , Transmission verticale de maladie infectieuse/prévention et contrôle , Jeune adulte , Agents antiVIH/usage thérapeutique , Adolescent , Complications infectieuses de la grossesse/traitement médicamenteux , Complications infectieuses de la grossesse/virologie
18.
Int J Gynaecol Obstet ; 166(1): 115-125, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38831742

RÉSUMÉ

OBJECTIVE: To explore the relationships between gestational hepatitis B virus (HBV) infection, antiviral therapy, and pregnancy outcomes. METHODS: We retrospectively selected hepatitis B surface antigen (HBsAg)-positive pregnant women hospitalized for delivery at Fujian Medical University Affiliated Hospital from October 1, 2016 to October 1, 2020. The control group included randomly selected healthy pregnant women hospitalized for delivery during the same time. RESULTS: Overall, 1115 participants were enrolled and grouped into control (n = 380) and HBsAg-positive groups (n = 735), which were further divided into groups I (n = 407; low viral load), II (n = 207; high viral load without antiviral therapy), and III (n = 121; high viral load with antiviral therapy). Pregnant women with HBV were positively correlated with the incidence of intrahepatic cholestasis of pregnancy (ICP) (adjusted odds ratio [aOR] 5.1, 95% confidence interval [CI] 2.62-9.92, P < 0.001), neonatal jaundice (aOR 10.56, 95% CI 4.49-24.83, P < 0.001), and neonatal asphyxia (aOR 5.03, 95% CI 1.46-17.27, P = 0.01). Aspartate aminotransferase (AST) greater than the upper limit of normal (ULN) was an independent risk factor for increased ICP incidence (aOR 3.49, 95% CI 1.26-9.67, P = 0.019). Antiviral therapy considerably reduced HBV DNA and improved liver function. High viral load and antiviral therapy did not correlate significantly with adverse pregnancy outcomes (P < 0.05). CONCLUSION: Pregnant women with HBV have significantly elevated incidence of ICP, neonatal jaundice, and neonatal asphyxia not significantly correlated with viral load. AST greater than ULN independently increases the risk of ICP. Antiviral therapy effectively reduces viral replication and improves liver function without increasing the risk of adverse outcomes.


Sujet(s)
Antiviraux , Hépatite B , Complications infectieuses de la grossesse , Issue de la grossesse , Charge virale , Humains , Femelle , Grossesse , Études rétrospectives , Antiviraux/usage thérapeutique , Complications infectieuses de la grossesse/traitement médicamenteux , Complications infectieuses de la grossesse/virologie , Adulte , Hépatite B/épidémiologie , Hépatite B/traitement médicamenteux , Cholestase intrahépatique/épidémiologie , Chine/épidémiologie , Antigènes de surface du virus de l'hépatite B/sang , Virus de l'hépatite B , Nouveau-né , Études cas-témoins , Ictère néonatal/épidémiologie , Complications de la grossesse
19.
PeerJ ; 12: e17481, 2024.
Article de Anglais | MEDLINE | ID: mdl-38881857

RÉSUMÉ

Background: COVID-19 is an infectious pathology that shows vascular changes during pregnancy, as well as in the placentas. The main objectives of this study were to estimate the prevalence and the risk factors for preeclampsia in hospitalized pregnant women with COVID-19. As well as comparing maternal and perinatal outcomes in hospitalized pregnant women with COVID-19 and preeclampsia with those without preeclampsia. Methods: Prospective cohort study of 100 hospitalized pregnant women from two tertiary hospitals, diagnosed with COVID-19, and divided into two groups: PE+ group (pregnant women with COVID-19 and preeclampsia) and PE- group (pregnant women with COVID-19 without preeclampsia). These pregnant women had prevalence, risk factors, maternal and perinatal data analyzed. Results: The prevalence of preeclampsia was 11%. Severe COVID-19 was the main risk factor for preeclampsia (OR = 8.18 [CI 1.53-43.52]), as well as fetal growth restriction was the main perinatal outcome (OR = 8.90 [CI 1.52-38.4]). Comorbidities were more frequent in the PE+ group (63.6% vs 31.5%, p = 0.03), as well as prematurity (81.8% vs 41.6%, p = 0.02), low birth weight (63.6% vs 24.7%, p = 0.01), and the need for neonatal intensive care admission of the newborn (63.6% vs 27.0%, p = 0.03). Pregnant women with PE had twice as long a length of stay in the intensive care unit (RR = 2.35 [CI 1.34-4.14]). Although maternal mortality was more frequent among pregnant women with PE, it was not statistically significant. Conclusions: Prevalence of preeclampsia in hospitalized pregnant women with COVID-19 was 11%. Severe COVID-19 was the main risk factor for preeclampsia and associated comorbidities increased the risk for developing preeclampsia. Long length of stay in the intensive care unit was the main maternal outcome and fetal growth restriction was the main perinatal outcome of preeclampsia.


Sujet(s)
COVID-19 , Pré-éclampsie , Complications infectieuses de la grossesse , Issue de la grossesse , SARS-CoV-2 , Centres de soins tertiaires , Humains , Grossesse , Femelle , Pré-éclampsie/épidémiologie , COVID-19/épidémiologie , COVID-19/mortalité , Brésil/épidémiologie , Études prospectives , Adulte , Complications infectieuses de la grossesse/épidémiologie , Complications infectieuses de la grossesse/virologie , Facteurs de risque , Issue de la grossesse/épidémiologie , Prévalence , Nouveau-né , Retard de croissance intra-utérin/épidémiologie , Retard de croissance intra-utérin/virologie , Comorbidité
20.
Infect Dis Obstet Gynecol ; 2024: 8844325, 2024.
Article de Anglais | MEDLINE | ID: mdl-38883209

RÉSUMÉ

Introduction: Transplacental infections are frequent, especially in developing countries, where limited screening is performed to find infectious agents in the pregnant population. We aim to determine the clinical and epidemiological characteristics and seroinfection of antibodies against Toxoplasma, parvovirus B19, T. pallidum, and HIV in pregnant women who attended the Motupe Health Center in Lambayeque, Peru during July-August 2018. Methods: A descriptive cross-sectional study was conducted in 179 pregnant women interviewed with a standardized questionnaire. ELISA was used to determine antibodies to Toxoplasma and parvovirus B19. The detection of syphilis and HIV was conducted using immunochromatography, while the detection of hepatitis B was conducted using FTA-ABS and immunofluorescence, respectively. Results: Of 179 pregnant women, syphilis and HIV infections routinely included in the screening of pregnant women presented a seroinfection of 2.2 and 0.6%, respectively. Toxoplasmosis seroinfection was 25.1%, while IgM antiparvovirus B19 was 40.8%, revealing that pregnant women had an active infection at the time of study. Conclusion: The level of seroinfection of toxoplasmosis reveals the risk to which pregnant women who participated in the study are exposed. The high seroinfection of parvovirus B19 could explain the cases of spontaneous abortion and levels of anemia in newborn that have been reported in Motupe, Lambayeque, Peru. However, future causality studies are necessary to determine the significance of these findings.


Sujet(s)
Infections à VIH , Parvovirus humain B19 , Complications infectieuses de la grossesse , Syphilis , Toxoplasma , Toxoplasmose , Treponema pallidum , Humains , Femelle , Grossesse , Pérou/épidémiologie , Treponema pallidum/immunologie , Adulte , Études transversales , Syphilis/épidémiologie , Complications infectieuses de la grossesse/épidémiologie , Complications infectieuses de la grossesse/virologie , Toxoplasmose/épidémiologie , Toxoplasmose/immunologie , Infections à VIH/épidémiologie , Toxoplasma/immunologie , Jeune adulte , Parvovirus humain B19/immunologie , Anticorps antiprotozoaires/sang , Anticorps antiviraux/sang , Adolescent , Études séroépidémiologiques
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...